Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Shuyu HaoGuanyou HuangJie FengDa LiKe WangLiang WangZhen WuHong WanLiwei ZhangJunting ZhangPublished in: Journal of neuro-oncology (2019)
Checkpoint inhibitors may be potential strategies for targeted immunotherapies of these mutant meningiomas.